TUSTIN, Calif., March 25, 2014 /PRNewswire/ -- American Society of Aesthetic Plastic Surgery (ASAPS) released their 2013 statistics for medical aesthetic procedures last week, and the results demonstrated a significant 16% gain in liposuction procedures over 2012 http://www.surgery.org/media/statistics. According to ASAPS, liposuction is the leading cosmetic surgical procedure and represents over 360,000 procedures among core aesthetic specialties. Also over $1 billion was spent on this procedure nationwide, as medical aesthetics achieved the highest volumes since the 2008 recession.
"This growth in the liposuction market is not at all unanticipated" said Tom Albright, CEO of Andrew Technologies. "Our pre-launch consumer market research (N=21,509) demonstrated that over 14 million U.S. adults are actively considering a liposuction procedure. Taking action on this interest was mainly limited by the capacity to pay and by finding surgeons that delivered excellent aesthetic results with limited risks or recovery time. Now that the economy is finally showing real improvement, we think the benefits of our innovative, non-cutting HydraSolve® Liposuction System make it perfectly suited for worldwide growth."
"We now have over 425 patients treated with HydraSolve® by 30 surgeons with excellent aesthetic results," said Mark S. Andrew, M.D., Chief Scientific Officer of Andrew Technologies. "We are thrilled to offer a superior outcome to patients and to surgeons that also reduces the risk of pain, bruising, sensation disorders, or surgical revision."
HydraSolve® is a novel liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device for precision cataract surgery. Hydrasolve® combines natural saline solution with low levels of temperature and pressure, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolve® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. HydraSolve® is the first liposuction device FDA cleared for autologous fat transfer. For more information, please refer to www.hydrasolve.com. HydraSolve® is designed to contour the body by removing localized deposits of excess fat and is not intended to treat obesity. Liposuction is a surgical procedure that has risks similar to other minimally invasive cosmetic surgeries.
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.
SOURCE Andrew Technologies